Affymax, Inc. (AFFY)
USD 0.0
(242.86%)
USD 0.0
(242.86%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2013 | 1.35 Million USD | -97.25% |
| 2012 | 49.41 Million USD | 3.55% |
| 2011 | 47.72 Million USD | -57.59% |
| 2010 | 112.52 Million USD | -2.07% |
| 2009 | 114.89 Million USD | 38.68% |
| 2008 | 82.85 Million USD | 86.87% |
| 2007 | 44.33 Million USD | 278.1% |
| 2006 | 11.72 Million USD | 15745.95% |
| 2005 | 74 Thousand USD | -50.99% |
| 2004 | 151 Thousand USD | -32.89% |
| 2003 | 225 Thousand USD | 118.45% |
| 2002 | 103 Thousand USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2014 Q1 | - USD | 100.0% |
| 2014 Q2 | 42 Thousand USD | 0.0% |
| 2013 Q2 | 522.76 Thousand USD | -37.33% |
| 2013 Q3 | 166.00 USD | -99.97% |
| 2013 Q4 | -52.00 USD | -131.33% |
| 2013 Q1 | 834.21 Thousand USD | 102.77% |
| 2013 FY | 1.35 Million USD | -97.25% |
| 2012 FY | 49.41 Million USD | 3.55% |
| 2012 Q4 | -30.15 Million USD | -321.64% |
| 2012 Q3 | 13.6 Million USD | 393.9% |
| 2012 Q2 | 2.75 Million USD | -95.64% |
| 2012 Q1 | 63.2 Million USD | 1619.04% |
| 2011 Q4 | 3.67 Million USD | -72.16% |
| 2011 FY | 47.72 Million USD | -57.59% |
| 2011 Q2 | 14.15 Million USD | -15.18% |
| 2011 Q3 | 13.2 Million USD | -6.66% |
| 2011 Q1 | 16.68 Million USD | 147.71% |
| 2010 Q2 | 54.34 Million USD | 56.84% |
| 2010 FY | 112.52 Million USD | -2.07% |
| 2010 Q4 | 6.73 Million USD | -59.89% |
| 2010 Q3 | 16.79 Million USD | -69.11% |
| 2010 Q1 | 34.65 Million USD | 5.12% |
| 2009 Q2 | 26.92 Million USD | 4.14% |
| 2009 FY | 114.89 Million USD | 38.68% |
| 2009 Q4 | 32.96 Million USD | 13.03% |
| 2009 Q3 | 29.16 Million USD | 8.31% |
| 2009 Q1 | 25.85 Million USD | 1.95% |
| 2008 Q3 | 21.64 Million USD | 13.16% |
| 2008 Q2 | 19.13 Million USD | 14.46% |
| 2008 Q4 | 25.35 Million USD | 17.14% |
| 2008 FY | 82.85 Million USD | 86.87% |
| 2008 Q1 | 16.71 Million USD | -0.8% |
| 2007 Q4 | 16.84 Million USD | 60.56% |
| 2007 Q2 | 9.66 Million USD | 32.02% |
| 2007 Q1 | 7.32 Million USD | 8.75% |
| 2007 FY | 44.33 Million USD | 278.1% |
| 2007 Q3 | 10.49 Million USD | 8.53% |
| 2006 Q4 | 6.73 Million USD | 39.1% |
| 2006 Q3 | 4.84 Million USD | 3334.04% |
| 2006 FY | 11.72 Million USD | 15745.95% |
| 2006 Q2 | 141 Thousand USD | 1662.5% |
| 2006 Q1 | 8000.00 USD | 14.29% |
| 2005 Q3 | 22 Thousand USD | 0.0% |
| 2005 Q1 | 22 Thousand USD | -42.11% |
| 2005 Q4 | 7000.00 USD | -68.18% |
| 2005 FY | 74 Thousand USD | -50.99% |
| 2005 Q2 | 22 Thousand USD | 0.0% |
| 2004 Q2 | 38 Thousand USD | 0.0% |
| 2004 Q1 | 38 Thousand USD | 0.0% |
| 2004 FY | 151 Thousand USD | -32.89% |
| 2004 Q4 | 38 Thousand USD | 0.0% |
| 2004 Q3 | 38 Thousand USD | 0.0% |
| 2003 FY | 225 Thousand USD | 118.45% |
| 2002 FY | 103 Thousand USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 55743.419% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 88.406% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 524.762% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 98.861% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 105.261% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 2912.207% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 1192.259% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 90.952% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -43650.58% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 86.143% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -1964.787% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 4074.064% |
| Mesoblast Limited | -35.16 Million USD | 103.859% |
| Marizyme, Inc. | 457.7 Thousand USD | -196.512% |
| Genus plc | 178.7 Million USD | 99.241% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.383% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -2080.99% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -230.877% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 12437.664% |
| ContraFect Corporation | -154 Thousand USD | 981.262% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 2814.286% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -1668.011% |
| IMV Inc. | -962.29 Thousand USD | 241.031% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 450.23% |
| MultiCell Technologies, Inc. | 49.32 USD | -2751609.246% |
| ONE Bio Corp. | 20.12 Million USD | 93.257% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 96.629% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -2675.344% |
| Q BioMed Inc. | -8988.00 USD | 15199.499% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 95.197% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 8898.904% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 96.94% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 218.884% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -1838.776% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 27505.957% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -865.938% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 1491.727% |
| GB Sciences, Inc. | -624.00 USD | 217590.865% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 1677.56% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.982% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 652572.596% |
| Enzolytics Inc. | 30.7 Thousand USD | -4319.51% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -181.312% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.878% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 363.774% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -119.822% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.669% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 15424.56% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 1718.556% |
| Kadimastem Ltd | -630.13 Thousand USD | 315.372% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -37.365% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 85.879% |
| BioStem Technologies, Inc. | 15.42 Million USD | 91.202% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 11567.199% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -668.658% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -668.658% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 4779.803% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -201.559% |
| SYBLEU INC | 11.69 Thousand USD | -11503.48% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 70.548% |
| Bioxytran, Inc. | -8285.00 USD | 16480.724% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 463.845% |
| Neutra Corp. | 14.33 Thousand USD | -9367.339% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 1755.052% |
| PureTech Health plc | -1.6 Million USD | 184.663% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 235.547% |
| IXICO plc | 3.27 Million USD | 58.497% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 295.554% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 175.776% |
| CSL Limited | 7.7 Billion USD | 99.982% |
| Cellectis S.A. | 18 Thousand USD | -7439.683% |